Trial · NCT01764633
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 6 months | 3.11 | 95% Confidence Interval 2.82 to 3.40 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 6 months | 2.74 | 95% Confidence Interval 2.47 to 3.01 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 12 months | 6.01 | 95% Confidence Interval 5.61 to 6.41 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 12 months | 5.31 | 95% Confidence Interval 4.93 to 5.68 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 18 months | 8.32 | 95% Confidence Interval 7.86 to 8.78 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 18 months | 7.25 | 95% Confidence Interval 6.81 to 7.68 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 24 months | 10.66 | 95% Confidence Interval 10.12 to 11.19 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 24 months | 9.13 | 95% Confidence Interval 8.63 to 9.63 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 30 months | 12.72 | 95% Confidence Interval 12.08 to 13.35 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 30 months | 10.91 | 95% Confidence Interval 10.31 to 11.50 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Placebo | KM estimate at 36 months | 14.64 | 95% Confidence Interval 13.76 to 15.50 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization | Evolocumab | KM estimate at 36 months | 12.57 | 95% Confidence Interval 11.70 to 13.42 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Placebo | KM estimate at 6 months | 1.86 | 95% Confidence Interval 1.63 to 2.08 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Evolocumab | KM estimate at 6 months | 1.65 | 95% Confidence Interval 1.44 to 1.86 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Placebo | KM estimate at 12 months | 3.68 | 95% Confidence Interval 3.36 to 3.99 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Evolocumab | KM estimate at 12 months | 3.10 | 95% Confidence Interval 2.81 to 3.38 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Placebo | KM estimate at 18 months | 5.18 | 95% Confidence Interval 4.81 to 5.55 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Evolocumab | KM estimate at 18 months | 4.29 | 95% Confidence Interval 3.95 to 4.62 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Placebo | KM estimate at 24 months | 6.83 | 95% Confidence Interval 6.39 to 7.26 | percentage of participants |
| Time to Cardiovascular Death, Myocardial Infarction, or Stroke | Evolocumab | KM estimate at 24 months | 5.47 | 95% Confidence Interval 5.08 to 5.86 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01764633/results